Kirsty's Mounjaro restart video raises questions about pausing

What did @keepingwithkirsty actually say?

Kirsty is five weeks off tirzepatide (Mounjaro) and restarting today at 0.5mg, skipping the standard 2.5mg starting dose. She weighs 79.6kg, up from a low of 75.5kg during her previous run. She explicitly says "I do not recommend this" about jumping straight to 0.5mg, and tells viewers to start at 2.5mg and work up if they're restarting. She also talks about wanting to reduce what she calls "inflammation" in her body, and plans to get back into gym training alongside the medication.

To be clear about the dosing: standard tirzepatide titration begins at 2.5mg weekly for four weeks before stepping up. Kirsty is doubling that starting dose on her own initiative. She's aware it's off-label behaviour and flags it. That self-awareness matters, but it doesn't neutralise the risk for viewers who might copy her without the same context.

Does the science back this up?

The rebound weight after stopping GLP-1 medications is well-documented and real. Her 4.1kg regain over five weeks is consistent with published data. The "inflammation" framing, though, is doing a lot of work here and deserves scrutiny.

The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed that participants who stopped tirzepatide after 36 weeks regained roughly two-thirds of their lost weight within a year. Five weeks of regain is a normal physiological response, not a sign of personal failure. The body defends its prior weight set point through hormonal and metabolic mechanisms, particularly through ghrelin and leptin signalling, and tirzepatide's dual GIP/GLP-1 agonism suppresses appetite in ways that reverse quickly after cessation.

On the inflammation claim: there is emerging evidence that tirzepatide reduces markers of systemic inflammation, including C-reactive protein and interleukin-6 (Frias et al., 2021, New England Journal of Medicine). But attributing belly bloating primarily to "inflammation" is imprecise. Visceral fat redistribution, gut motility changes after stopping the drug, and simple caloric rebound all contribute. Kirsty isn't wrong that something is happening, she's just using a loosely defined term for a complex set of changes.

What did they get wrong (or right)?

The titration advice she gives viewers is actually correct. Starting at 2.5mg and working up is the approved protocol, and she says so plainly. Credit where it's due. Her transparency about ignoring her own advice is unusual in this content space, where most creators present their choices as templates.

Where things get shaky: jumping to 0.5mg on restart. Tirzepatide's approved dosing schedule (TGA and FDA alike) starts at 2.5mg for a reason. The gastrointestinal side effects, nausea, vomiting, and delayed gastric emptying, are dose-dependent. Starting higher increases the likelihood of significant GI distress. There's no published evidence that resuming at a higher starting dose produces faster or better outcomes. A 2023 review by Nauck and D'Alessio in Nature Reviews Endocrinology notes that tolerability-driven titration is central to GLP-1 class safety, and skipping steps is explicitly discouraged in prescribing guidelines.

Her weight regain numbers are plausible and her self-monitoring is reasonable. She is not making any disease cure claims, which keeps her within safer territory than many GLP-1 creators on the platform.

What should you actually know?

If you're considering stopping and restarting tirzepatide, the evidence is clear: weight regain after stopping is expected, not exceptional. The SURMOUNT-4 data suggest that continuous treatment outperforms stop-start cycling for sustained weight loss, though cycling may be a practical reality for people managing cost or supply issues.

On restart dosing, the prescribing information is not ambiguous. You restart at 2.5mg. Your prescriber may adjust this based on your history and how long you were off the drug, but that is a clinical decision, not a personal one based on impatience. Starting too high does not speed up results. It increases the chance you'll spend the first two weeks feeling sick enough to quit again.

The "inflammation" narrative circulating in GLP-1 communities online often conflates several distinct things: visceral adiposity, gut microbiome shifts, actual inflammatory markers, and subjective bloating. These are related but not identical. Tirzepatide does appear to have anti-inflammatory effects beyond weight loss alone, but that is a research finding, not a feature you can feel in your belly after five weeks off the drug.

• Weight regain after stopping GLP-1 medications is a pharmacological expectation, not a willpower failure.
• Restart dosing should follow clinical guidance, starting at 2.5mg, not personal preference.
• The "inflammation" framing is imprecise. Some of what Kirsty describes is likely fluid shifts and visceral fat redistribution, not systemic inflammation.